• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment

    2022-11-05 03:54:04GuoQingYinKePingChenXiaoChunGu
    World Journal of Gastroenterology 2022年40期

    Guo-Qing Yin,Ke-Ping Chen,Xiao-Chun Gu

    Abstract Hepatitis B virus (HBV) infection is a global public health issue. Interferon-α (IFNα) treatment has been used to treat hepatitis B for over 20 years, but fewer than 5%of Asians receiving IFN-α treatment achieve functional cure. Thus, IFN-α retreatment has been introduced to enhance antiviral function. In recent years,immune-related studies have found that the complex interactions between immune cells and cytokines could modulate immune response networks, including both innate and adaptive immunity, triggering immune responses that control HBV replication. However, heterogeneity of the immune system to control HBV infection, particularly HBV-specific CD8+ T cell heterogeneity, has consequential effects on T cell-based immunotherapy for treating HBV infection.Altogether, the host’s genetic variants, negative-feedback regulators and HBV components affecting the immune system's ability to control HBV. In this study,we reviewed the literature on potential immune mechanisms affecting the immune control of HBV and the clinical effects of IFN-α treatment and retreatment.

    Key Words: Hepatitis B virus; Chronic; Functional cure; Heterogeneity; Immunity;Immune control; Interferon-α; Retreatment

    INTRODUCTION

    Hepatitis B virus (HBV) infection is a major global health problem. It is estimated that over 257 million people are suffering from chronic hepatitis B (CHB) infection[1]. After being infected by HBV, the virus transfers its genome into the nucleus of hepatocytes, where it is converted into covalently closed circular DNA (cccDNA), which has two major roles: Acting as a template for virus replication and acting as a reservoir for long-term virus preservation. Some studies have found that cccDNA persists in the hepatocytes of patients even decades after HBV infection has been resolved[2]. Further, it was shown that part of the viral genome remained integrated into the genomic DNA of the host’s hepatocytes.Therefore, targeted eradication of cccDNA and viral genome in hepatocytes is regarded as the holy grail for curing HBV[3-5], which has not yet been achieved with current therapies.

    HBV infection induces various immune responses that lead to heterogeneous immune control associated with the HBV infection[5,6]. Acute HBV infection can be terminated by the host’s adaptive immune responses, characterized by multi-specific and vigorous HBV-specific CD8+T cell responses. In contrast, during CHB infection, the adaptive immune responses are severely depressed due to exhausted or reduced HBV-specific CD8+T-cells[6,7]and dysfunctions in HBV-specific B cells[7-9].Researchers have noticed different outcomes from HBV infection in different populations and races.

    Most CHB cases in the Asian population occur during infancy or childhood. However, asymptomatic infection during childhood makes it very challenging for authorities to determine when the infection actually occurred. Further, due to the uncertain timing of hepatitis flares and disease phases, there is little research on this topic in past literature, and little is known about hepatitis flares and intrahepatic immunity. Recently, studies on the partial immune mechanism in CHB have been performed, and important discoveries were made[2-6].

    Currently, CHB is treated with nucleoside/nucleotide analogs (NAs) or interferon-α (IFN-α). NAs can target HBV polymerase/reverse transcriptase, inhibit HBV replication and are better tolerated by patients, but they cannot target cccDNA and unavoidably often results in NAs resistance and associated mutations. Since NAs do not directly influence immune response, functional cure with NAs is rarely achieved. In contrast, IFN-α treatment enhances HBV-specific immune control and can result in a partial or functional cure. However, due to poor efficacy with single course IFN-α treatment, since 1996,researchers have begun using IFN-α retreatment to improve the antiviral efficacy in CHB patients[10-15]or sufferers from NAs multi-drugs resistance[15-18].

    In this present article, we reviewed the complex interactions between immune cells and cytokines of the immune response network against HBV, the correlation between host genetic variations and hepatitis B, the interplay between HBV components and HBV-specific immune control, and the heterogeneity of HBV-specifical immune control. Based on this foundation, we also discussed the underlying mechanism of IFN-α treatment and retreatment for improved HBV-specific immune control.

    HETEROGENEOUS IMMUNITIES DURING HBV INFECTION

    The innate and adaptive immunity work together to control immune responses against HBV. Innate immunity is not HBV antigen-specific but still produces T-cell polarizing and inflammatory cytokines that alter the intrahepatic microenvironment for presenting HBV antigens to na?ve T cells to establish HBV-specific immunity. In recent years, researchers have recognized adaptive immunity as a crucial player for persistent and efficient immune control of HBV infection, which comprises a complex web of effector cell types. HBV-specific T cells help clearing HBV-infected hepatocytes and reduce the levels of circulating virus, while B cells neutralize viral particles and prevent reinfection[3,19-22]. Thus, their levels ultimately determine the outcome of the disease.

    The liver is an immunologically tolerant organ in which most immune cells are suppressed to limit hypersensitivity of immune responses against organ damage and local antigens. Thus, in a healthy state,the proportion of immune cells within the liver is much lower than in the peripheral blood. The difference in immune statuses between the liver and peripheral blood is defined as “immune compartmentalization”. Investigations into the effects of costimulation have shown that Toll-like receptors(TLRs) and Treg cells participate in the intrahepatic immunopathogenesis in patients with HBV infection[3,23-25].

    Recognition of HBV components by the innate immunity

    Non-specific recognition of HBV components occurs at the molecular/subcellular level by innate immunosensors, namely pathogen-recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMP). The main PRRs that sense viral infection consists of retinoic acid-inducible gene I (RIG-I)-like receptors, nucleotide-binding oligomerization domain-containing protein-like receptors, TLRs, DNA-sensing receptors and C-type Lectin. These PRRs are expressed in epithelial cells,endothelial cells and immune cells. When PRRs interact with their cognate PAMP, downstream signaling pathways cascade, including adaptor/co-adaptor molecules, kinases and transcription factors are activated. This leads to the expression of interferon-stimulated genes (ISGs) and NFκB-inducible or pro-inflammatory genes, and various inflammatory cytokines are secreted. Primary cytokines include various classes of IFNs, pro-inflammatory cytokines and chemokines. These cytokines recruit various immune cells to the HBV-infected site, causing direct or indirect antiviral actions. These immune responses induce T cell proliferation and increase the efficiency of HBV-specific CD8+ T cells[21,26,27].In particular, TLRs in hepatocytes and hepatic non-parenchymal cells (NPCs) have been shown to play vital roles in antiviral immunity. Currently, the use of TLR agonists as therapeutic agents to treat CHB is being validated[7].

    In addition to cytokines, innate effector cells also participate in the control of HBV infection. Innate effector cells, including natural killer (NK) cells, γδT cells and mucosal-associated invariant T cells, can restrain the virus but are not specific for controlling HBV. Activated NK cells can induce inflammation in the liver, while activated T cells can be killed by NK cells, thereby reducing HBV-specific T cells.Although NK cells can suppress HBV replication, their activity was shown to be inhibited by transforming growth factor β (TGF-β) and IL-10 in CHB patients[3]. In addition, hepatic PCs, such as KCs and liver sinusoidal endothelial cells, can stimulate innate and adaptive immunity against HBV infection[28,29].

    In short, the activation of innate immunity can lead to the production of cytokines, enhance antigen presentation, alter the intrahepatic microenvironment and trigger adaptive immunity (Figure 1).

    HBV infection and adaptive immunity

    HBV-specific T cells play a vital role in controlling HBV infection, and their immune responses can lead to the resolution of HBV replication. In acute hepatitis B patients, spontaneous viral clearance can occurviamulti-specific CD8+T cell responses against HBV components[3,30]. In contrast, in CHB, the patients suffer from the exhaustion of HBV-specific CD8+T-cell responses throughout the HBV infection. Thus,most research on immune dysfunction focus on the activity of T cells, including CD8+and CD4+T-cells.

    CHB is associated with the exhaustion of HBV-specific CD8+T-cells, marked by compromising functionality, such as reduced production of antiviral cytokines and immunodulatory cytokines and impaired proliferative capacities, defined as T-cell exhaustion[31,32]. HBV-specific CD8+T-cell exhaustion can be induced by: (1) Gradual aggravation of CD8+T-cells dysfunction and decreasing inflammatory cytokines production; (2) Increase in checkpoint inhibitors and immunosuppressive cytokines; (3) Epigenetic alterations leading to unrecoverable CD8+T-cell functions; (4) Alterations in CD8+T-cell phenotype; (5) Mitochondrial dysfunction and glycolysis downregulation, (6) Decrease in cell detection rate; and (7) Terminal exhaustion and physical deletion of HBV-specific CD8+T-cells.

    In acute hepatitis B, CD4+T-cells have an important but indirect role in cleaning the virus. Th1-polarized CD4+T-cells regulate and maintain CD8+T-cell responses, contributing to HBV clearance. In contrast, during chronic HBV infection, the activation and upregulation of CD4+CD25+Treg-cells suppress effective antiviral immune responses by inhibiting IFN-γ secretion, which inhibits the proliferation and cytokine secretion of CD4+and CD8+T-cells[7,30]. Figure 1 illustrates the complex interactions between immune cells and cytokine within the immune response network. The immune cells and their related cytokines are presented in Table 1.

    HBV components inhibit innate and acquired immunity

    HBV is believed to have existed in the human population for thousands of years and evolved with humans. During this evolution process, HBV has developed a particular lifecycle based on its unique replication mode through cccDNA and viral components that can adapt and suppress its host's immunity. Although the innate immunity can differentiate between different HBV components, HBV virion, antigens and peptides are still able to attack the TLR signaling pathway, resulting in negligible ISGs or IFNs secretions[4,7].

    Table 1 Immune cells and their corresponding cytokines released

    Among the ISGs is the apolipoprotein B editing complex (APOBEC) gene. APOBEC3A/B has been shown to cause cccDNA degradation, while APOBEC3G can inhibit HBV replication. However,APOBEC3G expression is often reduced by HBsAg[32].

    A viral protein known for influencing HBV replication is HBx. It can interact with the cellular proteins in hepatocytes to increase viral replication by impairing IFN signaling and enhancing HBV gene expression[33-35]. Further, it was shown that HBV antigens could inhibit CD8+T-cell efficiency.Antagonist functions may provide a means for HBV to escape immune detection. Considering that certain CD8+T-cell epitopes in hepatitis B core antigen (HBcAg) or HBsAg can act as T-cell receptor(TCR) antagonists, their binding to TCR can lead to the suppression of CD8+T-cell response, thus decreasing their efficiency (Figure 2). In addition, the chronicity of HBV infection was shown to be promoted by HBeAgviathe induction of CD8+T-cell tolerance[36].

    Mechanisms of immune escape in antigen-presenting cells/HBV specific-CD8+ T-cells

    When the HBV protein is swallowed by antigen-presenting cells (APCs), this protein is digested into tiny pieces, which are transferred onto human leukocyte antigen (HLA) antigens. The HLA antigen complex on APCs is then displayed to T cells, which produce effector molecules to eliminate HBV.However, when HBV enters a hepatocyte, it enhances intracellular survival at the expense of higher levels of HBV replication. Thus, HBV-infected hepatocytes produce a large number of HBV antigens that can, in turn, inhibit HBV antigen processing and presentation in APCs. Further, amino acids flanking the viral epitopes in APCs play a critical role in antigen processing. Mutations at these regions in HBV infection harm the proteasomal processing of epitopes and lead to CD8+T-cell escape[30].

    HLA genes are critical for the immune system as they control pathogens and clear infections. Host HLA polymorphisms have been demonstrated to influence disease progression in HBV infection[37].Studies found that changes in the surface expression of HLA class I complexes on APCs were associated with HBV replication and persistence. Lower HLA class I expression led to early HBeAg seroconversion, while down-regulation of HLA class II molecules led to pre-core mutants of HBcAg[38].Lumleyet al[30]focused on the interplay between the immune escape of HBV and the selective mutation of HLA-binding residues. They reported that this selective mutation of HLA-binding residues in CD8+epitopes could induce the immune escape of HBV, which is one of the most commonly identified mechanisms for HBV-specific CD8+immune escape[30].

    N-linked glycosylation (NLG) is a post-translational modification that can impact the infectivity and antigenicity of HBV. It can mask immune epitopes, leading to immune escape and interfering with the antibody recognition of hepatitis B surface antigen. NLG can also affect the ability through which the envelope protein of HBV interacts with the surface of capsids to drive HBV virion secretion[30].

    The connection between TCR on T-cell and HLA class I/peptide complexes induces the activation of CD8+T-cells, but alterations in TCR recognition,i.e., epitope mutations in TCR contact residues, can lead to the immune escape of CD8+T-cells. Immunodominance of HBV epitopes is ensured by the amino acid sequence of the peptide and its concentration and binding affinity with T cell clones. In different CD8+T-cell clones, the same viral peptide can induce different signaling cascades[22]. Figure 2 illustrates the immune escape of HBV, which can occur through multiple pathways. This has a vital role in HBV infection that can last for decades, with some T cell defects being irreversible.

    Figure 1 Crosstalk among immune cells and cytokines in hepatitis B virus infection. The complex interactions among immune cells and cytokines in chronic hepatitis B are shown. Hepatitis B virus (HBV)-specific CD8+ T-cells are activated by monocytes and CD4+ T-cells, followed by recruitment and activation of macrophages by active CD8+ T-cells. The activation of natural killer (NK) T-cells is induced by Kupffer cells, which activate NK cells and hepatic stellate cells (HSCs).Suppressive Tregs, Bregs and Kupffer cells induce the functional impairment of CD8+ T cells, CD4+ T-cells and NK cells. Moreover, Treg cells, Kupffer cells and myeloid-derived suppressor cells can lead to the exhaustion of CD8+ T-cells and NK cells. Inflammatory and inhibitory cytokines, including Monocyte chemoattractant protein-1, tumor necrosis factor-α, interferon-γ, interleukin (IL)-4, IL-6, IL-12, IL-13, IL-17, IL-10, and transforming growth factor-β, are involved in the crosstalk among immune cells. The activation of HSCs in sinusoids is induced by a complement protein such as C5a. Finally, decreasing epigenetic modification and function of HBVspecific CD8+ T-cells inhibits the immune control of HBV. PD-1: Programmed death 1; CTLA-4: Cytotoxic T-lymphocyte antigen-4; IL: Interleukin; TNF-α: Tumor necrosis factor-α; TGF-β: Transforming growth factor β; IFN-γ: Interferon-γ; HSC: Hepatic stellate cell; MDSC: Myeloid-derived suppressor cells; NK: Natural killer.

    Negative feedback regulation in immune response pathways

    Negative feedback regulations commonly occur in immune response pathways. These regulations include negative regulation of immune signal pathways (i.e., negative feedback regulation in TLRs pathway), activation of immune checkpoints, expression of inhibitory cytokines, and activation of inhibitory immune cells. An active innate immunity can induce the secretion of cytokines with antiviral activity, enhance the efficiency of APCs and alter the microenvironment of the liver. However, inflammatory cytokines such as IFNs and tumor necrosis factor-α (TNF-α) can induce immune tolerance[39-41]. Many immune cells and signaling pathways in the liver contribute to immune responses against HBV infection. These immune responses are contact-dependent and can be affected by environmental factors. Inhibitory molecules are produced by hepatic stellate cells, Kupffer cells, T-regulatory cells and myeloid-derived suppressor cells. Through a contact-dependent manner, NK cells can kill HBV-specific CD8+T-cells. Moreover, HBV-specific CD8+T-cells can be suppressed by inhibitory ligands such as programmed death-ligand 1 (Figure 1)[6,42]. However, considering HBV has adaptive and active strategies to evade innate immune responses and negative feedback exists in all immune responses,immune regulator therapy targeting only a single pathway is unlikely to be effective in treating HBV infection.

    Host genetic variations associated with HBV infection

    Researchers have made great efforts to confirm the associations between HBV infection and host immunogenetics. Host genetic variants, including mutations in TLRs, HLAs, vitamin D-related genes,cytokine and chemokine genes, microRNAs, and HBV receptor sodium taurocholate co-transporting polypeptide, have been observed to impact the outcomes of HBV infection (Table 2)[43-46]. The HLA genes are divided into two classes: HLA-class I (HLA-A, B, C, E, F and G) and HLA-class II (HLA-DP,DQ, DR, DM and DO). Polymorphisms in HLA genes were shown to be significantly associated with thepathogenesis of HBV infection[47,48]. Studies have also reported that the genes encoding cytokines such as interleukins, TNF-α, IFNs and TGF-β, can influence the immune state of CHB patients[49-53]. In a study by Nitschkeet al[54], the authors confirmed that specific HLA class I alleles restricted the efficacy of HBV-specific CD8+T-cells[54], indicating that the host’s immune-related genes can affect the outcome of hepatitis B infection.

    Table 2 Host genetic variants associated with hepatitis B virus infection[43-46]

    Haplotypes:1G-A-G-A-T-T, rs9277535-rs10484569-rs3128917-rs2281388-rs3117222-rs9380343.2G-G-G-G-T-C, rs9277535-rs10484569-rs3128917-rs2281388-rs3117222-rs9380343.3A-A, rs3077-rs9277535.4A-A, rs2395309-rs9277535.5T-A-T, rs3077-rs9277378-rs3128917.6C-A-T, rs3077-rs9277378-rs3128917.7A-A-C-T, rs2395309-rs3077- rs2301220-rs9277341.8A-A-C-C//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343.9A-A-C-T//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343.10G-G-T-C//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343;11T-T-G-A-T, rs9276370-rs7756516-rs7453920- rs9277535-rs9366816.12T-T-G-G-T, rs9276370-rs7756516-rs7453920-rs9277535-rs9366816.13G-A, rs2856718- rs9275572.14A-G, rs2856718- rs9275572.15A-A, rs2856718- rs9275572.16T-C-C-G-G-G, -1031/-863/-857/-308/-238/-163.17C-A-C-G-G-G, -1031/-863/-857/-308/-238/-163.18A-T-G-T-T-T-T-C-T, +88344/+102906/+103432/+103437/+103461/+104261/+104802/+106151/+106318.19T-C, rs12375841-rs17803780.20C-A-C, rs421446-rs107822-rs213210.21T-G-T, rs421446-rs107822-rs213210.22C-A-C-C-G, -1722/-1661/-658/-319/+49.23T/C-A-C-C-G, -1722/-1661/-658/-319/+49.24T-A-C-C-A, -1722/-1661/-658/-319/+49.25A-T-A, rs17401966-rs12734551-rs3748578.26C-C, rs111033850-rs12953258.27T-T-C-T-A, -1800/-1627/+4645/+5806/+6139.28C-T-C-T-T, rs8179673-rs7574865-rs4274624-rs11889341-rs10168266.29G-G-A, rs3757328-rs6940552-rs9261204.SNPs/Hap/CNVs: Single nucleotide polymorphisms/Haplotype/Copy number variations; HLA: Human leukocyte antigen; TLR: Toll-like receptors.

    Figure 2 Mechanism of immune escape in antigen-presenting cell/hepatitis B virus special T-cell. Hepatitis B virus (HBV)-infected hepatocytes produce various HBV antigens that are swallowed and digested by antigen-presenting cells (APCs), producing HBV peptide/human leukocyte antigen (HLA)complexes. Antigen processing escape mutants, down-regulating HLA expression and mutation of HLA binding residues may appear in APCs. The HBV peptide/HLA complexes are transferred to the surface of APC and make contact with T-cell receptor (TCR) on the surface of CD8+ T-cells. Masking HLA/TCT binding residues with N-linked glycosylation and mutation of TCR binding residues influences TCR affinity/avidity, leading to CD8+ T-cell stimulation or inhibition. The square icon displays:(1) Increase in viral antigen; (2) Antigen processing escape mutants; (3) Down-regulation of HLA expression; (4) Mutation of HLA binding residues; (5) Masking of HLA/TCT binging residues with N-linked glycosylation; (6) Mutation of TCR binding residues; (7) Stimulation induced by cytokine production and cytolytic activity; and(8) Inhibition caused by exhaustion, anergy and tolerance. HBV: Hepatitis B virus; TCR: T-cell receptor; HLA: Human leukocyte antigen.

    Researchers have observed significant differences in HBV infection rates between Western and East/Southeast Asian populations. Prior to HBV vaccination programs, the prevalence of HBsAg was less than 1% in the Caucasian population but higher than 10% in the Chinese population[43]. This difference was investigated in several studies, which showed that HLA molecules in European,Caucasian, Middle East, African-American and Asian populations affected the rate of HBV infection[43,55,56]. In addition, discordances in HBV-specific CD8+T-cell repertoires observed in different races, i.e.,between Chinese and Caucasian populations, could be related to race-dependent HLA gene variants,leading to the different T-cell responses observed between different populations and ethnicities[57].

    Thus, these findings underline the complexity of HBV-specific immune control efficacy, which is influenced by HBV components, negative feedback regulation in immunity and host genetic variants(Figure 3).

    Heterogeneity of immune control in HBV infection

    Figure 3 Interplay between hepatitis B virus-specific immune control, hepatitis B virus components, and negative feedback regulation in immunity and host genes. HBV: Hepatitis B virus.

    Heimet al[6]reviewed the heterogeneity of HBV-specific CD8+T-cells and described the functional deficiencies and distinct phenotypical characteristics associated with HBV-specific CD8+T-cells exhaustion. T-cell impairment demonstrates hierarchical and progressive loss in antiviral functions,from functional suppression to physical deletion in T-cells, which depend on the quantity of HBV antigens and the duration of T cell exposure to these antigens[31,58]. Moreover, exhausted CD8+T-cells do not represent a homogeneous T-cell population but are rather heterogeneous in function and phenotype. Kuiperyet al[5]proposed concepts related to the heterogeneity of immune responses in CHB patients[5]. Based on reports from literature, we summarized the following concepts to improve our understanding on the heterogeneity of immune control.

    Figure 1 illustrates the activation and inhibition of immune signaling pathways that overlap in HBV infection, multiple immune cell populations and integrated signals pathways that simultaneously respond to the stimulation of HBV components, and the ability of HBV-specific immune control depends on the overall immune responses of an individual rather than the capability of single immune cells or a single immune pathway.

    Based on the immune escape mechanisms of APCs/CD8+T-cells presented in Figure 2, the heterogeneous immune responses of T-cells are related to very fine mechanisms of immune regulation that influence the immune control of HBV-specific T-cells, or T-cells sensitivity/inhibition.

    Figure 3 outlines the reasons for heterogeneous immune control. The overall immune control against HBV in an individual is influenced by HBV, negative feedback regulation in the immune signaling network and host genetic variants. Therefore, any changes in these three countenances could lead to fluctuations affecting the effectiveness of immune control. Thus, CHB infection is divided into four clinical phases: Immune tolerant with HBeAg-positive, HBeAg-positive immune-activation, inactive carrier with HBeAg-negative, and HBeAg-negative immune-activation. Further, heterogeneous immune controls can lead to different clinic phases and disease outcomes such as acute hepatitis, chronic hepatitis, cirrhosis, hepatocellular carcinoma and hepatic failure[43].

    Reports have shown that host genetic polymorphisms are crucial determinants influencing HBV infectious rate and disease outcomes in Caucasian, Saudi Arabian, African-American, European, and Asian populations[56,59,60]. In addition, the host genetic variants of individuals from the same race can influence disease outcomes and the efficacies of antiviral therapy.

    Researcher and immunologists who often overlook immune compartmentalization should be cautious when interpreting findings from the peripheral blood of patients.

    IFN-α TREATMENT FOR CHB

    Definition of partial cure and functional cure

    A complete cure from HBV infection is currently hypothesized to be possible if the cccDNA and integrated HBV DNA are eliminated from hepatocytes. However, this is challenging as cccDNA can still persist in patients despite spontaneous recovery from an acute HBV infection. Since 2017, some advances in CHB therapeutics have been achieved[61], and researchers have proposed new definitions of cure. For instance, a partial cure has been defined as persistently undetectable HBV DNA and HBeAg in patients’ serum after the completion of a limited course of antiviral therapy. Functional cure has been defined as sustained and undetectable HBV DNA and HBsAg in patients’ serum, with or without seroconversion to hepatitis B surface antibody (anti-HBs), after a limited course of therapy. Complete sterilizing cure has been defined by the absence of HBsAg and eradication of HBV DNA, including HBV virion, integrated HBV DNA and cccDNA in the liver and serum of patients. However, because current treatments cannot deliver complete sterilizing cure, functional cure is the selected goal of therapy.

    NAs and immunotherapy

    Therapeutic strategies for CHB can be classified into two categories: NAs targeting HBV replication and immune modulators targeting immune control. NAs can cause rapid decay of HBV DNA in the peripheral blood but cannot completely eradicate HBsAg from patients' serum and cccDNA in hepatocytes[62,63]. Even though the virus might be undetectable in the serum after long-term treatment with NAs, low-level viral replication still persists due to the conservation of cccDNA in the nucleus of hepatocytes. Thus, prolonged NAs treatments are rarely associated with CHB cure and inevitably result in either NAs resistance or viral relapse[62-66].

    In contrast, immunotherapy can target the innate and adaptive immunity to reinvigorate the host immune response to long-term inhibition of viral replication. Therapeutic strategies involving innate immunity include activating pattern recognition receptors (i.e., TLRs and RIG-I), enhancing cytokine secretion, and improving the efficacy of NK cells. For adaptive immunity, therapies are directed at restoring the effects of HBV-specific T-cells and B-cells. Clinically, although immunotherapy can lead to sustained HBsAg loss, it cannot eradicate cccDNA from hepatocytes. Thus, being the more promising treatment compared to NAs, the ultimate goal of immunotherapy is currently targeted at achieving functional cure, enabling spontaneous control of HBV replication and maintaining disease remission without antiviral therapy[3]. Hoogeveen and Boonstra[32]reported that immunomodulators regulating a single immune pathway might not restore antiviral immunity as multiple immune pathways in the host enhance specific HBV immune responses[32].

    Mechanism and clinical application of IFN-α therapy

    IFNs are produced and released by immune cells in response to HBV components[67,68]. Of the known IFNs, IFN-α has broad-spectrum effects on viruses and tumors, and contributes to immune regulation by suppressing viral replication and cell growth. The antiviral function of IFN-α is cascaded by binding to IFN receptors on immune cells, activating signal transcription pathways, and inducing ISGs expression and related product secretion. Various ISGs products were found to inhibit different stages of the viral life cycle[69]. Further, epigenetics was shown to play a critical role in regulating cccDNA transcription[70-73]. IFN-α can regulate the epigenetic repression of cccDNA transcription by inducing cccDNA-bound histone hypo-acetylation and increasing the recruitment of transcription co-repressor on cccDNA[63,65,73]. In addition, IFN-α can upregulate HLAs expression to activate innate and adaptive immune responses. Many researchers have investigated the host genes associated with IFN-α treatment outcomes and observed its genetic polymorphisms[43,44,74-78](Table 3).

    As described earlier, due to negative feedback mechanisms, immune modulators targeting a single signal pathway might not improve the overall and long-term immune responses[61]. In this regard, the advantages of IFN-α treatment are that IFN-α can simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals to improve the efficacy of immune control[10,11,15,36]. Currently, only IFN-α treatment was found to improve the efficacy of immune control[64,65].

    IFN-α has been approved for the treatment of hepatitis B for over 20 years[36,61,65]. Compared with NAs, IFN-α has shown better efficacy in HBeAg seroconversion and HBsAg loss, with no risk of drug resistance[79]. For groups of patients with good prognoses, such as Caucasians, young age, low viral load, and females, IFN-α treatment has been more effective[80,81]. One study reported functional cure in 10%-20% of Caucasians who underwent IFN-α treatment, while it was < 5% in Asian patients[82].However, most of the underlying mechanisms of IFN-α therapy are still unclear. More research is needed to investigate these significant differences in IFN-α efficacy between different groups of patients.

    Table 3 Host genetic variants associated with interferon-α therapy[43,44,74-78,91]

    IMPROVEMENT OF HBV-SPECIFIC IMMUNE CONTROL BY IFN-α RETREATMENT

    IFN-α retreatment

    In 1996, although IFN-α was already being used to treat CHB patients, only 20%-30% of the patients achieved viral suppression or partial cure with single IFN-α treatment. Then, it was found that IFN-α retreatment in these remaining patients could enhance treatment outcomes. Thus, multiple courses of IFN-α were implemented to treat these patients and researchers observed that three courses of IFN-α treatment were effective in treating HBeAg positive or negative patients. With multiple frequencies of IFN-α treatment, partial or functional cure rates gradually increased to approximately 25%-40% but were mostly observed in patients of white race[10-14](Table 4).

    By 2008, failures from combination therapy with nucleoside and nucleotide were reported, and multidrug resistance with NAs treatment started to increase in China. Comparatively, IFN-α retreatment was associated with safe stopping of NAs administration and induced better-sustained responses to IFN-α[15]. Thus, when researchers started to investigate the effects of increasing the frequency and extending the total course of IFN-α treatment and found that these could significantly improve the rate of functional cure in Asian and Caucasian patients[73-75,80-83]. IFN-α retreatment was recommended by the Asian-Pacific clinical practice guidelines[16-18]and by Yinet al[64](Table 4). Based on these promising findings and recommendations, we estimate that more CHB patients in Asia would receive IFN-α retreatment and experience better antiviral efficacy.

    Interplay between IFN-α retreatment and the HBV-specific immune control

    Recently, more and more HBV-specific immune mechanisms have been discovered, inspiring clinicians and immunologists to collaborate to study the interplay between immune mechanisms and clinical events in hepatitis B. Changet al[84]summarized the relationship between hepatitis flare and immune responses in CHB patients to explore the underlying immune mechanism of hepatitis flares[84]. The observations made from the strategy of Chang'set al[84]involved in IFN-α retreatment.

    Table 4 Summary and timeline of interferon-α retreatment for chronic hepatitis B virus infection

    Asymptomatic persistence of cccDNA in the liver of patients who had acute hepatitis B or selflimiting HBV infection, despite the resolution of HBV infection[3], indicates that the host’s immune system can fully inhibit HBV replication and that the specific HBV immune control in these individuals had an overwhelming advantage over HBV replication. In addition, investigations on the heterogeneous immune control of HBV infection have shown that the heterogeneity depends on the interplay between the host, virus and therapy, including host genes and immunity state, HBV load, duration of HBV infection, and IFN-α treatment and course of treatment[5,6,31,58]. However, the exact mechanismviawhich IFN-α retreatment exerts its benefits is yet to be fully elucidated.

    Apart from HBV load, HBsAg and HBeAg, markers associated with the immune control of IFN-α treatment are lacking. In a study by Konerman and Lok[79], the authors proposed a scoring system that could help assess the efficacy of immune control[79]. The type of immune control could be estimated from a patient’s HBV DNA, HBeAg seroconversion, HBsAg loss and times of IFN-α treatment, based on the following criteria: (1) Patients with acute hepatitis B or self-limiting HBV infection could achieve automatic cure without IFN-α treatment; (2) Patients with acute hepatitis B could achieve functional cure with one time IFN-α treatment; (3) CHB patients with one time IFN-α treatment could achieve functional cure; (4) CHB patients with one time IFN-α treatment could achieve partial cure; (5) CHB patients with multiple times of IFN-α treatment could achieve functional cure; and (6) CHB patients with multiple times of IFN-α treatment could achieve partial cure. These criteria suggest a step-like decline in immune control with increasing infection severity.

    Clinical studies have confirmed that IFN-α retreatment could gradually increase the rate of partial and functional cure (Table 4)[10,11,13,15,36]and that CHB patients often have diverse HBV-specific immune control. Since 2016, researchers in China have reported numerous findings from clinical trials in which patients with inactive HBsAg carriers or low-level viremia were selectively enrolled and treated with IFN-α to evaluate their functional cure rate[85-88]. However, it should be noted that these were performed under trial settings because clinical guidelines do not recommend IFN-α therapy for the treatment of CHB in these patients[16,89,90]. A high rate of functional cure, 44.7%-84.2% of HBsAg loss and 20.2%-68.2% of HBsAg seroconversion were reported, in which a distinctive pattern of immune control whereby a close correlation between lower HBsAg at baseline and higher rates of HBsAg loss or HBsAg seroconversion was observed[85-88]. This pattern also appeared in the final course of IFN-α retreatment in previous studies[10,11,13,15,36], indicating that reducing HBsAg could be a prerequisite for achieving functional cure during IFN-α retreatment.

    Taken together, current literature indicates that IFN-α retreatment could gradually enhance the overall immune control and improve the antiviral efficacy of IFN-α in CHB patients (Figure 4).

    Figure 4 Interferon-α retreatment improves the efficacy of hepatitis B virus-specific immune control. Interferon-α (IFN-α) retreatment can lead to various treatment outcomes, namely no response, hepatitis B virus (HBV) decline, partial cure and functional cure. Multiple frequencies of IFN-α treatment can potentially restore specific immune control to HBV infection and simultaneously increase the rate of partial cure and functional cure. A: Exhausted immune control to HBV before IFN-α therapy (Baseline); B: Without HBV decline following IFN-α therapy; C: HBV decline; D: Partial cure; E: Functional cure. CHB: Chronic hepatitis B.

    CONCLUSION

    The interactions between immune cells and cytokines form a complex immune response network that exerts immune control over HBV infection. The efficacy of HBV-specific immune control is affected by HBV components, negative feedback regulation in the immune system, host genetic variants, and heterogeneity in the function and phenotype of immune control to HBV. Treatment with IFN-α can simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals to improve the efficacy of immune control. Clinically, increasing the frequency and extending the total course of IFN-α retreatment have improved functional cure rates, indicating that IFN-α retreatment could gradually enhance the overall immune control. Further research on IFN-α retreatment could help promote this strategy in CHB patients with.

    Altogether, this article outlined immune control without detailed discussions on immunity-related markers during immune transformation. In future studies, the discovery of detailed markers associated with immune transformation could provide important clues in understanding the underlying mechanism of immune control to improve the treatment of HBV infection.

    ACKNOWLEDGEMENTS

    We are very grateful to Prof. Gao-Jun Teng in Zhong-Da Hospital, Southeast University and Prof. Bei Zhong in the sixth Affiliated Hospital of Guangzhou medical University/Qingyuan People’s Hospital for the comprehensive evaluation of the manuscript and valuable advices. Authors acknowledge Dr.Cun Shan in the Department of infectious disease, Nanjing Zhong-Da Hospital for data collection.

    FOOTNOTES

    Author contributions:All authors contributed to the study conception and design; The first draft of the manuscript was written by Yin GQ; All authors commented on previous versions of the manuscript, they all read and approved the final manuscript.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Guo-Qing Yin 0000-0002-8972-3752; Ke-Ping Chen 0000-0002-8601-7481; Xiao-Chun Gu 0000-0002-7289-8054.

    S-Editor:Fan JR

    L-Editor:A

    P-Editor:Fan JR

    国产精品国产av在线观看| 建设人人有责人人尽责人人享有的| √禁漫天堂资源中文www| 日韩一卡2卡3卡4卡2021年| 在线看a的网站| 国产一区二区激情短视频 | 亚洲精品在线美女| 亚洲精品成人av观看孕妇| 天美传媒精品一区二区| 日韩成人av中文字幕在线观看| 亚洲精品久久久久久婷婷小说| 边亲边吃奶的免费视频| 中文天堂在线官网| 亚洲一区二区三区欧美精品| 亚洲美女视频黄频| 国产精品一国产av| 大话2 男鬼变身卡| 亚洲欧美一区二区三区黑人 | 97在线视频观看| 国产精品一区二区在线不卡| 色吧在线观看| 欧美日韩精品成人综合77777| 亚洲国产av新网站| 欧美中文综合在线视频| 亚洲成国产人片在线观看| av免费在线看不卡| 国产精品免费大片| 午夜久久久在线观看| 多毛熟女@视频| 欧美另类一区| 国产成人91sexporn| 国产成人91sexporn| 爱豆传媒免费全集在线观看| 97在线视频观看| 亚洲 欧美一区二区三区| 视频区图区小说| 边亲边吃奶的免费视频| 波野结衣二区三区在线| 久久国产精品大桥未久av| 亚洲成色77777| 欧美精品人与动牲交sv欧美| 街头女战士在线观看网站| 亚洲av电影在线进入| 99国产精品免费福利视频| 国产亚洲欧美精品永久| 免费女性裸体啪啪无遮挡网站| 成年女人在线观看亚洲视频| 国产精品国产av在线观看| 美女中出高潮动态图| 国产午夜精品一二区理论片| 欧美变态另类bdsm刘玥| 成人午夜精彩视频在线观看| 蜜桃在线观看..| 人人妻人人爽人人添夜夜欢视频| 人人妻人人澡人人爽人人夜夜| 色94色欧美一区二区| 成人亚洲欧美一区二区av| 黄频高清免费视频| 亚洲精品自拍成人| 一区二区三区精品91| 国产精品成人在线| 少妇人妻 视频| 一区二区三区四区激情视频| 免费黄网站久久成人精品| 九草在线视频观看| 亚洲av成人精品一二三区| 丝袜美足系列| 国产又爽黄色视频| 亚洲av日韩在线播放| 精品久久蜜臀av无| 亚洲欧美日韩另类电影网站| 日韩在线高清观看一区二区三区| 制服诱惑二区| 嫩草影院入口| 久久久久久久亚洲中文字幕| 日韩一本色道免费dvd| 免费av中文字幕在线| 亚洲欧美精品综合一区二区三区 | 少妇人妻 视频| 久久精品国产综合久久久| 亚洲国产精品国产精品| 欧美激情高清一区二区三区 | 亚洲四区av| 巨乳人妻的诱惑在线观看| 男女免费视频国产| 亚洲欧洲日产国产| 亚洲精品在线美女| 欧美最新免费一区二区三区| xxx大片免费视频| a级毛片黄视频| 日韩电影二区| 黄片无遮挡物在线观看| 欧美日韩国产mv在线观看视频| 91成人精品电影| 国产免费福利视频在线观看| 国产日韩一区二区三区精品不卡| 久久久久久久国产电影| 国产成人精品久久久久久| 又粗又硬又长又爽又黄的视频| 亚洲一区中文字幕在线| 久久这里有精品视频免费| 1024视频免费在线观看| 观看美女的网站| 18禁观看日本| 日本-黄色视频高清免费观看| av网站在线播放免费| 日韩 亚洲 欧美在线| 欧美老熟妇乱子伦牲交| 视频区图区小说| 咕卡用的链子| 国产精品国产av在线观看| 欧美精品一区二区免费开放| 嫩草影院入口| 国产av一区二区精品久久| 国产精品国产三级专区第一集| 精品第一国产精品| 久久精品国产a三级三级三级| 欧美日韩一区二区视频在线观看视频在线| 又粗又硬又长又爽又黄的视频| 狂野欧美激情性bbbbbb| 黄色配什么色好看| 一本—道久久a久久精品蜜桃钙片| 国产精品嫩草影院av在线观看| 成年动漫av网址| 亚洲成av片中文字幕在线观看 | 亚洲综合精品二区| 成人午夜精彩视频在线观看| 五月伊人婷婷丁香| 亚洲精品日本国产第一区| 另类亚洲欧美激情| 国产 一区精品| 日日爽夜夜爽网站| 午夜福利视频在线观看免费| 免费人妻精品一区二区三区视频| 久久午夜福利片| 少妇精品久久久久久久| 国产精品无大码| 少妇猛男粗大的猛烈进出视频| 国产日韩欧美亚洲二区| 日产精品乱码卡一卡2卡三| 国产成人av激情在线播放| 丝瓜视频免费看黄片| 国产免费福利视频在线观看| 免费观看性生交大片5| 亚洲少妇的诱惑av| 午夜福利网站1000一区二区三区| 看免费av毛片| 男人添女人高潮全过程视频| 99香蕉大伊视频| 亚洲国产欧美网| 午夜影院在线不卡| 国产黄频视频在线观看| 日韩欧美精品免费久久| 午夜免费观看性视频| 国产精品一国产av| 国产片特级美女逼逼视频| 欧美黄色片欧美黄色片| 各种免费的搞黄视频| 国产精品99久久99久久久不卡 | 制服诱惑二区| 国产片特级美女逼逼视频| 国产毛片在线视频| 亚洲国产欧美在线一区| 久热久热在线精品观看| 男女下面插进去视频免费观看| 伦理电影免费视频| 涩涩av久久男人的天堂| 久久99蜜桃精品久久| 丝袜美足系列| 欧美黄色片欧美黄色片| 一本—道久久a久久精品蜜桃钙片| 最近的中文字幕免费完整| 成年人免费黄色播放视频| 中国三级夫妇交换| 国产精品国产三级国产专区5o| 精品酒店卫生间| 日韩中文字幕视频在线看片| 热re99久久精品国产66热6| 亚洲经典国产精华液单| 欧美精品av麻豆av| 乱人伦中国视频| 欧美精品一区二区大全| 久久久久久久精品精品| 久久精品aⅴ一区二区三区四区 | 丰满饥渴人妻一区二区三| 国产一区二区三区综合在线观看| 国产精品欧美亚洲77777| 国产精品久久久久久久久免| av网站免费在线观看视频| 看免费av毛片| 国产精品国产av在线观看| 日韩不卡一区二区三区视频在线| 日韩一区二区三区影片| 成人亚洲精品一区在线观看| 国产精品一区二区在线不卡| 国产色婷婷99| 少妇人妻 视频| 日韩 亚洲 欧美在线| 女人久久www免费人成看片| 亚洲综合色网址| 亚洲精品在线美女| 免费观看在线日韩| 一二三四中文在线观看免费高清| 日韩在线高清观看一区二区三区| 少妇的丰满在线观看| 麻豆精品久久久久久蜜桃| 免费高清在线观看日韩| 人人澡人人妻人| 91成人精品电影| 国产黄频视频在线观看| 老司机亚洲免费影院| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 国产精品久久久久久精品电影小说| 老汉色av国产亚洲站长工具| 777米奇影视久久| 如何舔出高潮| 欧美亚洲 丝袜 人妻 在线| 国产日韩欧美亚洲二区| 肉色欧美久久久久久久蜜桃| 最近中文字幕高清免费大全6| 男人添女人高潮全过程视频| 国产成人免费观看mmmm| 亚洲国产欧美日韩在线播放| 18在线观看网站| 欧美日韩国产mv在线观看视频| 日韩在线高清观看一区二区三区| 午夜激情久久久久久久| 999久久久国产精品视频| 天天操日日干夜夜撸| 最近中文字幕高清免费大全6| 男人添女人高潮全过程视频| 亚洲美女视频黄频| 成人二区视频| 亚洲欧美一区二区三区黑人 | 精品国产乱码久久久久久男人| 美女xxoo啪啪120秒动态图| 亚洲精品一区蜜桃| 超色免费av| 国产在视频线精品| 亚洲成色77777| 亚洲av电影在线观看一区二区三区| 99久久人妻综合| 男女啪啪激烈高潮av片| 校园人妻丝袜中文字幕| 欧美精品亚洲一区二区| 五月伊人婷婷丁香| 中文欧美无线码| 人人妻人人添人人爽欧美一区卜| 嫩草影院入口| 香蕉精品网在线| 黄片小视频在线播放| 日韩一本色道免费dvd| 各种免费的搞黄视频| av国产久精品久网站免费入址| 丰满饥渴人妻一区二区三| 看免费成人av毛片| 国产国语露脸激情在线看| 亚洲欧美一区二区三区国产| 亚洲第一区二区三区不卡| 中文字幕av电影在线播放| 国产午夜精品一二区理论片| 一边亲一边摸免费视频| 国产亚洲精品第一综合不卡| 久久久精品国产亚洲av高清涩受| 蜜桃国产av成人99| 亚洲精品,欧美精品| a级毛片黄视频| 久久久久久久久久人人人人人人| 国产精品女同一区二区软件| 国产又色又爽无遮挡免| 十分钟在线观看高清视频www| 如何舔出高潮| 亚洲色图 男人天堂 中文字幕| 下体分泌物呈黄色| 国产成人精品无人区| 王馨瑶露胸无遮挡在线观看| 欧美黄色片欧美黄色片| 久久ye,这里只有精品| 国产成人精品一,二区| av福利片在线| 老汉色∧v一级毛片| 成人毛片a级毛片在线播放| 嫩草影院入口| 亚洲经典国产精华液单| 卡戴珊不雅视频在线播放| 人妻一区二区av| √禁漫天堂资源中文www| 久久久国产欧美日韩av| 国产麻豆69| 老汉色∧v一级毛片| 亚洲av中文av极速乱| 2021少妇久久久久久久久久久| 久久久久久久久久久免费av| 亚洲熟女精品中文字幕| 丰满饥渴人妻一区二区三| 一级片免费观看大全| 性色avwww在线观看| 国产欧美亚洲国产| 久久99热这里只频精品6学生| 久久毛片免费看一区二区三区| 一本—道久久a久久精品蜜桃钙片| 18禁观看日本| 国产极品粉嫩免费观看在线| 午夜精品国产一区二区电影| 青草久久国产| 9热在线视频观看99| 国产熟女欧美一区二区| 亚洲综合精品二区| 在线天堂最新版资源| 免费观看无遮挡的男女| 国产成人精品福利久久| 久久青草综合色| 久久av网站| 多毛熟女@视频| 日韩视频在线欧美| 国产成人精品婷婷| 日韩电影二区| www.精华液| 波多野结衣av一区二区av| 亚洲欧洲国产日韩| 九九爱精品视频在线观看| 国产精品成人在线| 国产精品久久久久久精品古装| 亚洲精品日韩在线中文字幕| 在线免费观看不下载黄p国产| 欧美精品一区二区大全| 欧美精品亚洲一区二区| 亚洲激情五月婷婷啪啪| 亚洲五月色婷婷综合| 欧美精品人与动牲交sv欧美| 日韩 亚洲 欧美在线| 国产免费福利视频在线观看| 色婷婷久久久亚洲欧美| 亚洲精品aⅴ在线观看| 久久国内精品自在自线图片| 在线看a的网站| 国产精品久久久久成人av| 国产精品一区二区在线观看99| av在线播放精品| 精品少妇黑人巨大在线播放| 欧美日韩视频高清一区二区三区二| 成人午夜精彩视频在线观看| 欧美精品av麻豆av| 久久久精品免费免费高清| 亚洲国产欧美在线一区| 国产精品香港三级国产av潘金莲 | 黑丝袜美女国产一区| 一区二区三区四区激情视频| 五月开心婷婷网| 日日摸夜夜添夜夜爱| 十八禁网站网址无遮挡| 高清不卡的av网站| 国产成人精品在线电影| 亚洲成人手机| 叶爱在线成人免费视频播放| 精品久久久精品久久久| av.在线天堂| 夜夜骑夜夜射夜夜干| 亚洲成人av在线免费| 久久韩国三级中文字幕| 免费高清在线观看日韩| 夜夜骑夜夜射夜夜干| 中文字幕另类日韩欧美亚洲嫩草| 在现免费观看毛片| 母亲3免费完整高清在线观看 | 久久精品人人爽人人爽视色| videossex国产| 国产高清不卡午夜福利| 亚洲精品国产av成人精品| 国产精品av久久久久免费| 午夜日韩欧美国产| 人体艺术视频欧美日本| 好男人视频免费观看在线| 免费高清在线观看日韩| 国产精品久久久久成人av| 黄频高清免费视频| av女优亚洲男人天堂| 欧美精品人与动牲交sv欧美| 韩国av在线不卡| 免费高清在线观看视频在线观看| 999精品在线视频| 街头女战士在线观看网站| 亚洲成人一二三区av| 日本色播在线视频| 国产爽快片一区二区三区| 最新中文字幕久久久久| 国产在线一区二区三区精| 美女国产视频在线观看| 亚洲第一av免费看| 一边亲一边摸免费视频| 亚洲视频免费观看视频| 精品少妇久久久久久888优播| 亚洲久久久国产精品| 精品少妇久久久久久888优播| 欧美日本中文国产一区发布| 91精品国产国语对白视频| 久久女婷五月综合色啪小说| 婷婷色综合www| 亚洲av日韩在线播放| 欧美日韩av久久| 麻豆av在线久日| 国产精品免费视频内射| 欧美精品一区二区免费开放| 伊人久久大香线蕉亚洲五| 亚洲伊人久久精品综合| 少妇精品久久久久久久| 97在线视频观看| 1024香蕉在线观看| av国产精品久久久久影院| 国产精品.久久久| 久久精品国产综合久久久| 欧美日韩一区二区视频在线观看视频在线| 曰老女人黄片| 国产黄频视频在线观看| 亚洲精品国产av蜜桃| 亚洲欧洲国产日韩| 国产一区有黄有色的免费视频| 久久久国产一区二区| 久久这里有精品视频免费| 国产精品一区二区在线不卡| 免费大片黄手机在线观看| 国产精品久久久久久av不卡| 欧美xxⅹ黑人| 免费黄色在线免费观看| 日本午夜av视频| 999久久久国产精品视频| 色婷婷av一区二区三区视频| 日本欧美视频一区| 制服人妻中文乱码| 伦理电影大哥的女人| 国产免费一区二区三区四区乱码| 最近最新中文字幕大全免费视频 | 中文字幕精品免费在线观看视频| 美女大奶头黄色视频| 侵犯人妻中文字幕一二三四区| 青草久久国产| av线在线观看网站| 亚洲av福利一区| 人妻 亚洲 视频| 久久午夜综合久久蜜桃| 亚洲中文av在线| 日韩免费高清中文字幕av| 久久人人爽人人片av| 婷婷色麻豆天堂久久| 老汉色∧v一级毛片| 国产精品秋霞免费鲁丝片| 一个人免费看片子| 国产亚洲最大av| 中文字幕人妻丝袜一区二区 | 18禁观看日本| 日韩中文字幕视频在线看片| 久久久欧美国产精品| 人人妻人人添人人爽欧美一区卜| 大香蕉久久网| 日本欧美国产在线视频| 日韩一本色道免费dvd| 免费日韩欧美在线观看| 亚洲第一区二区三区不卡| 午夜激情av网站| 国产精品 国内视频| 色婷婷久久久亚洲欧美| 大话2 男鬼变身卡| 久久精品夜色国产| 欧美bdsm另类| 国产xxxxx性猛交| av天堂久久9| 精品酒店卫生间| 欧美人与性动交α欧美软件| 麻豆av在线久日| 晚上一个人看的免费电影| 美女大奶头黄色视频| 妹子高潮喷水视频| 国产成人免费观看mmmm| 亚洲人成网站在线观看播放| 91在线精品国自产拍蜜月| 国产av精品麻豆| 亚洲国产色片| 哪个播放器可以免费观看大片| 久久人人97超碰香蕉20202| 成人国语在线视频| 蜜桃在线观看..| 亚洲婷婷狠狠爱综合网| 黑丝袜美女国产一区| 下体分泌物呈黄色| 丝袜人妻中文字幕| 亚洲精品中文字幕在线视频| 最近最新中文字幕免费大全7| 久久久精品免费免费高清| 看免费av毛片| 天堂中文最新版在线下载| 欧美成人午夜精品| 国产一区二区在线观看av| 巨乳人妻的诱惑在线观看| 成人漫画全彩无遮挡| 日韩熟女老妇一区二区性免费视频| 99久久精品国产国产毛片| 欧美亚洲 丝袜 人妻 在线| 丝瓜视频免费看黄片| 国产精品免费大片| 亚洲精品久久久久久婷婷小说| 午夜精品国产一区二区电影| 一级片'在线观看视频| 99re6热这里在线精品视频| 午夜91福利影院| 电影成人av| 18禁动态无遮挡网站| 国产精品人妻久久久影院| 国产伦理片在线播放av一区| 久久精品国产综合久久久| 久久久亚洲精品成人影院| 中文字幕制服av| 亚洲综合色网址| 精品少妇黑人巨大在线播放| av不卡在线播放| 成人手机av| 亚洲精品一区蜜桃| 国产亚洲最大av| 国产精品一区二区在线观看99| a 毛片基地| 欧美激情 高清一区二区三区| 美女福利国产在线| 电影成人av| 精品99又大又爽又粗少妇毛片| 爱豆传媒免费全集在线观看| 人妻一区二区av| 夜夜骑夜夜射夜夜干| 大香蕉久久成人网| videos熟女内射| 久久影院123| 99国产综合亚洲精品| 欧美成人午夜精品| 女人精品久久久久毛片| 亚洲国产精品999| 亚洲综合精品二区| 91aial.com中文字幕在线观看| 精品亚洲乱码少妇综合久久| 国产片内射在线| 女性生殖器流出的白浆| 九色亚洲精品在线播放| 国产精品秋霞免费鲁丝片| 欧美变态另类bdsm刘玥| 91精品伊人久久大香线蕉| a级毛片在线看网站| 男人舔女人的私密视频| 日韩av免费高清视频| 精品人妻熟女毛片av久久网站| 中文字幕精品免费在线观看视频| 如日韩欧美国产精品一区二区三区| 丁香六月天网| 久久久久久久久免费视频了| 肉色欧美久久久久久久蜜桃| 亚洲av综合色区一区| 亚洲av福利一区| 看免费成人av毛片| 欧美日韩av久久| 视频区图区小说| 日韩欧美一区视频在线观看| 嫩草影院入口| av在线观看视频网站免费| 久久精品国产鲁丝片午夜精品| 中文字幕最新亚洲高清| 久久久久久久久久人人人人人人| 日韩中文字幕欧美一区二区 | 日韩av在线免费看完整版不卡| 日日啪夜夜爽| 黑人欧美特级aaaaaa片| 日本免费在线观看一区| 久热久热在线精品观看| 欧美中文综合在线视频| 老司机影院毛片| 性色av一级| 爱豆传媒免费全集在线观看| 久久鲁丝午夜福利片| 97人妻天天添夜夜摸| 精品一区二区免费观看| 深夜精品福利| 亚洲精品日本国产第一区| 国产国语露脸激情在线看| 蜜桃在线观看..| 国产精品久久久久成人av| 99香蕉大伊视频| 午夜福利一区二区在线看| videossex国产| 国产精品无大码| 成年动漫av网址| av国产久精品久网站免费入址| 成人手机av| 亚洲国产看品久久| 亚洲婷婷狠狠爱综合网| 日产精品乱码卡一卡2卡三| av在线老鸭窝| 久久精品久久精品一区二区三区| 亚洲第一区二区三区不卡| 丝袜在线中文字幕| 国产精品三级大全| 熟女电影av网| 女人被躁到高潮嗷嗷叫费观| 熟女少妇亚洲综合色aaa.| 亚洲人成77777在线视频| 久久久精品区二区三区| 一边亲一边摸免费视频| 人人妻人人澡人人爽人人夜夜| 人妻系列 视频| 日日撸夜夜添| 亚洲久久久国产精品| 九色亚洲精品在线播放| 国产97色在线日韩免费| 国产欧美亚洲国产| 一级黄片播放器| 在线观看三级黄色| 波野结衣二区三区在线| 成人二区视频| 男女高潮啪啪啪动态图| 欧美xxⅹ黑人| 久久精品国产a三级三级三级|